Matches 1 - 50 out of 83 1 2 >


Match Document Document Title
US20110280939 ORAL PARTICLE INCLUDING PSEUDOEPHEDRINE HYDROCHLORIDE AND CETIRIZINE DIHYDROCHLORIDE  
The present invention relates to an oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride, which primarily includes a nucleus having a diameter ranging 25˜40 mesh, a...
US20120128771 TIMED, PULSATILE RELEASE SYSTEMS  
A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles...
US20110091542 BACLOFEN AND R-BACLOFEN GASTRORETENTIVE DRUG DELIVERY SYSTEMS  
A biodegradable, multi-layered controlled release gastroretentive baclofen or R-baclofen dosage form which is optionally divided into a first dosage of baclofen or R-baclofen for immediate release...
US20120121702 Controlled Release Azithromycin Solid Dosage Forms  
A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.
US20140112985 METHOD OF PREVENTION AND TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION  
This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its...
US20140370085 Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same  
An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
US20110123613 EXTENDED-RELEASE DOSAGE FORM  
Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially...
US20150104506 ORALLY AVAILABLE PHARMACEUTICAL FORMULATION SUITABLE FOR IMPROVED MANAGEMENT OF MOVEMENT DISORDERS  
The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g....
US20070264326 Anti-misuse oral microparticle medicinal formulation  
The field of the present invention is that of solid microparticulate analgesic oral medicines. The invention is that of providing novel analgesic medicines which allow at the same time the...
US20150010625 Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof  
A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in...
US20140037723 Low Dose Topiramate/Phentermine Composition And Methods Of Use Thereof  
A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in...
US20110262535 Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof  
A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in...
US20120276017 Methods and Compositions for Treatment of Attention Deficit Disorder  
Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of...
US20120058182 METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT  
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
US20120045508 METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT  
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
US20110064804 Methods and Compositions for the Treatment of CNS-Related Conditions  
The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions...
US20110064803 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2  
The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an...
US20140287037 EXTENDED-RELEASE TOPIRAMATE CAPSULES  
An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein...
US20130004573 CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE  
The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug...
US20080175903 Treatment of anxiety with eszopiclone  
The present disclosure provides a unit dosage form with an anxiolytic dosage of zopiclone particularly eszopiclone. Also provided is a method for treatment or prophylaxis of anxiety using a...
US20110287096 MODIFIED GASTRORETENTIVE DRUG DELIVERY SYSTEM FOR AMINE DRUGS  
Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR...
US20140044780 Extended-Release Levetiracetam and Method of Preparation  
Described herein is a pharmaceutical composition comprising levetiracetam as an active ingredient to provide prolonged release characteristic to allow once a day dosage regime. The innovative...
US20140127291 EXTENDED RELEASE ACETAMINOPHEN LIQUID PHARMACEUTICAL COMPOSITIONS  
Disclosed herein is an extended release liquid pharmaceutical composition comprising extended release particles dispersed in a liquid medium. The extended release particles comprise acetaminophen...
US20090092658 NOVEL FORMULATIONS OF PROTON PUMP INHIBITORS AND METHODS OF USING THESE FORMULATIONS  
The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability,...
US20130078304 CONTROLLED RELEASE FORMULATION FOR TREATING SLEEP DISORDERS  
The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form...
US20120321708 SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE  
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the...
US20140050784 PHARMACEUTICAL COMPOSITIONS OF MEMANTINE  
The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for...
US20100068267 COMPOSITIONS FOR TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY  
The invention provides methods of treating a cardiovascular disease comprising administering a sustained release formulation of hydralazine hydrochloride and at least one of isosorbide dinitrate...
US20070178149 Levodopa compositions  
The invention provides compositions of levodopa resulting in extended absorption profiles and methods of treatment using the compositions.
US20050186269 Stabilized feverfew formulations  
The present invention is directed to compositions, methods of delivery and packaged nutraceuticals of a stabilized Feverfew Extract. More specifically, the stabilized Feverfew extract contains at...
US20050100594 Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor  
Disclosed is an extended release pharmaceutical formulation comprising a muscle relaxant drug, such as tizanidine, in combination with a cyclooxygenase-2 inhibitor, such as valdecoxib. The...
US20080003281 Modified Release Tablet Formulations for Proton Pump Inhibitors  
An oral solid pharmaceutical dosage form comprising an acid sensitive proton pump inhibitor (PPI) as single active drug, releasing the PPI in two separate pulses, one immediate and one delayed....
US20110229566 Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof  
There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts...
US20080226712 Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles  
The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is...
US20080014260 SOLID DISPERSING VACCINE COMPOSITION FOR ORAL DELIVERY  
The invention disclosed herein relate to an oral vaccine in which the vaccine composition and adjuvant(s) are carried on a solid fast-dispersing dosage form. The vaccines are targeted toward...
US20090169618 Zolpidem pharmaceutical compositions  
The present invention provides extended release pharmaceutical compositions comprising zolpidem or a salt thereof.
US20100266684 METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT  
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
US20100260838 METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT  
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
US20120128772 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN  
A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90% of the...
US20110117192 CARBIDOPA/LIPODOPA GASTRORETENTIVE DRUG DELIVERY  
A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more...
US20090169617 Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix  
A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in need of treatment in a single dose,...
US20100040680 MULTIPARTICULATE SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR FORMULATION  
A multiparticulate oral pharmaceutical composition that contains a plurality of delayed release coated selective serotonin and norepinephrine reuptake inhibitor particles.
US20090169619 CARBAMAZEPINE EXTENDED RELEASE DOSAGE FORM  
Extended release pharmaceutical dosage forms of carbamazepine for oral administration to maintain a patient's blood concentration for at least a 12 hour period, methods of administering dosage...
US20090060994 Controlled release azithromycin solid dosages forms  
A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.
US20050271718 Sustained release propafenone hydrochloride capsules  
A sustained release capsule for oral administration containing tablets, wherein each tablet comprises 25 mg propafenone hydrochloride.
US20110223247 PHARMACEUTICAL COMPOSITIONS FOR RELEASE CONTROL OF METHYLPHENIDATE  
Disclosed is a pharmaceutical composition for release control comprising a plurality of particles for release control. The plurality of particles for release control comprise a core material...
US20100270183 STABLE DIGESTIVE ENZYME COMPOSITIONS  
Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies....
US20070202162 EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS  
The present invention relates to extended release pharmaceutical compositions comprising a beta-blocker drug or a pharmaceutically acceptable salt thereof, wherein said composition comprises at...
US20080118557 SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE  
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the...
US20100151015 Compositions Comprising Melperone and Controlled-Release Dosage Forms  
The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a core comprising melperone and a controlled-release...

Matches 1 - 50 out of 83 1 2 >